Exelixis, Inc. (EXEL)
NASDAQ: EXEL · Real-Time Price · USD
36.20
-0.35 (-0.96%)
At close: Jan 17, 2025, 4:00 PM
36.36
+0.16 (0.44%)
After-hours: Jan 17, 2025, 7:58 PM EST
Exelixis Revenue
Exelixis had revenue of $539.54M in the quarter ending September 30, 2024, with 14.33% growth. This brings the company's revenue in the last twelve months to $2.08B, up 17.31% year-over-year. In the year 2023, Exelixis had annual revenue of $1.83B with 13.60% growth.
Revenue (ttm)
$2.08B
Revenue Growth
+17.31%
P/S Ratio
5.15
Revenue / Employee
$1,589,006
Employees
1,310
Market Cap
10.34B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1.83B | 219.15M | 13.60% |
Dec 31, 2022 | 1.61B | 176.09M | 12.27% |
Dec 31, 2021 | 1.43B | 447.43M | 45.31% |
Dec 31, 2020 | 987.54M | 19.76M | 2.04% |
Dec 31, 2019 | 967.78M | 113.95M | 13.35% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 87.70B |
Merck & Co. | 63.17B |
AbbVie | 55.53B |
AstraZeneca | 51.21B |
Novartis AG | 49.94B |
Thermo Fisher Scientific | 42.37B |
Abbott Laboratories | 41.22B |
EXEL News
- 8 days ago - Exelixis Announces Preliminary Fiscal Year 2024 Financial Results, Provides 2025 Financial Guidance and Outlines Key Priorities and Milestones for 2025 - Business Wire
- 10 days ago - The Best Defensive Stocks To Hedge Against Market Uncertainty - Seeking Alpha
- 11 days ago - Exelixis: Bullish On Cabo, Not So Convinced By It's Long-Term Replacement, Zanza - Seeking Alpha
- 11 days ago - Exelixis Provides Update on Oncologic Drugs Advisory Committee Meeting for Cabozantinib (CABOMETYX®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors - Business Wire
- 14 days ago - Exelixis to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025 - Business Wire
- 7 weeks ago - Exelixis to Webcast Fireside Chats as Part of Investor Conferences in December - Business Wire
- 7 weeks ago - Exelixis Provides Regulatory Update Related to Supplemental New Drug Application for Cabozantinib (CABOMETYX®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors - Business Wire
- 2 months ago - Exelixis to Webcast Fireside Chats as Part of Investor Conferences in November - Business Wire